$GSK··On the fence
GSK: A Mixed Bag of Signals
GSK caught my attention today due to a couple of recent developments that have stirred the pot for this pharmaceutical giant. The company's new drug, efimosfermin, has received re...
#FDA
6 posts
$CE··On the fence
Is CE a Good Buy After Roche's Recent Approval?
I’ve been keeping an eye on CE lately, especially after Roche received CE approval for their Elecsys ApoE4 biomarker test. This approval could be a significant catalyst for the co...
$GE··On the fence
General Electric: A Mixed Bag with Potential Upside and Risks
General Electric GE has been capturing attention lately, not least because of some recent developments that could have significant implications for its future. GE HealthCare just...
$JNJ··Bullish
Johnson & Johnson: A Steady Anchor in Uncertain Times
Johnson & Johnson JNJ caught my eye today, not just because it's a household name, but because it's been getting a lot of buzz for its reliability and potential to anchor a retirem...
$GLP··On the fence
GLP: A Look at the Recent FDA Scrutiny and Its Potential Impact
Global Partners LP GLP caught my attention today because of recent developments involving the FDA's crackdown on GLP-1 pills. Hims & Hers Health, a company that had been offering...
$LLY··Bullish
Is Eli Lilly (LLY) a Buy? Here's What I Think
Eli Lilly LLY has been grabbing attention lately, not just for its massive market cap of nearly $949 billion, but also due to some pretty impressive growth projections. Analysts a...